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Abstract
Several experimental and clinical studies have shown that a variety of ototoxic agents (such as drugs, industrial chemicals 
and noise) can cause sensorineural hearing loss. The most common ototoxic drugs used in clinical practice include: 
aminoglycoside and macrolide antibiotics, quinoline anti-malarials, platinum analog antineoplastics, loop diuretics, and 
acetylsalicylic acid. Among chemical agents with potential ototoxic properties are: organic solvents, heavy metals, organo-
tins, nitriles, asphyxiants, and pesticides/herbicides. Acoustic exposure to high intensity and/or prolonged noise can also 
cause permanent threshold shifts in auditory perception. ototoxic agents can influence auditory function by different 
mechanisms: roS overload, inhibition of mitochondrial protein synthesis, DnA/rnA damage, activation of the apoptotic 
pathways, excessive calcium influx, increase of proinflammatory cytokines, interference with fluid and electrolyte balance 
of the endolymph, atrophy of the stria vascularis, changes in blood-labyrinth barrier and overstimulation of the stereocilia 
of the ear cells. Since noise exposure and many drugs or chemical compounds frequently share the same ototoxic mecha-
nisms, this may explain why hearing loss can be potentiated by combined exposure to these agents. However, a great 
variability in the individual’s response to a given xenobiotic exists and depends on a complex interplay between endogenous 
and exogenous factors.
Key words: ototoxicity, hearing loss, pharmacological injury, reactive oxygen species
Introduction
robust evidence from a large number of experimen-
tal and clinical studies indicates that ototoxic agents 
such as drugs, chemical agents, and excessive noise 
exposure can cause permanent hearing damage sub-
sequent to acute or chronic prolonged exposure 
(Table I). Acoustic damage can manifest as impaired 
ability to discriminate sounds, hearing loss or bal-
ance disorders. These symptoms are caused by func-
tional changes to the inner ear, resulting from the 
detrimental action on the organ of Corti, vestibular 
organ, and/or vestibular-cochlear nerve exerted by 
the xenobiotic or noise (1,2). The different ototoxic 
agents can damage the inner ear in its entirety, spe-
cific cells within the organ, individual components of 
specific cells within the inner ear, or specific intracel-
lular biochemical pathways. Hearing damage gener-
ally appears after exposure to sufficiently high doses 
of the drug or chemical for a relatively long time. The 
damage usually develops gradually, starts at the high 
frequencies and subsequently progresses toward the 
lower frequencies. Cochlear damage is often initially 
asymptomatic or it may present with tinnitus (1,3,4). 
The tinnitus can be preceded by vestibular damage, 
causing vertigo, headache, nausea, vomiting, ataxia 
or nystagmus, although, at the beginning, these 
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symptoms can be compensated and masked by cen-
tral mechanisms such as visual stimuli and deep pro-
prioceptive sensations. However, the tinnitus is not 
always the expression of organic lesions of the cochlea 
or of the acoustic nerve, but could also be induced 
by an increase of labyrinth fluid (endolymph and 
perilymph), thus causing excessive stimulation of 
cochlear hair cells (5). Various biological mechanisms 
responsible for the hearing damage have been pro-
posed, including oxidative stress and increased for-
mation of highly reactive free radicals, the so-called 
reactive oxygen species (roS), lipid peroxidation, 
inhibition of mitochondrial protein synthesis, DnA 
and rnA damage, activation of the pro-apoptotic 
pathways, and interference with fluid- and electro-
lyte-balance within the endolymph. Interestingly, 
some of these mechanisms are shared by both oto-
toxic agents and noise (6–16).
However, an individual’s response to a given oto-
toxic agent is highly variable, and relies on a complex 
interplay among several endogenous and exogenous 
factors (Table II). Thus, the effects of the ototoxic 
agents are influenced by several pharmacokinetic 
parameters, and, in particular, by their clearance, a 
measure of the body’s efficiency in eliminating 
endogenous and exogenous substances. This variable 
is highly dependent on some demographic parame-
ters such as gender and age; thus, dosing adjustment 
of the drug becomes critical for safe therapeutics. 
In particular, most drug-metabolizing enzymes are 
expressed at low level at birth; therefore, their elimi-
nation is reduced in the neonatal period. on the other 
hand, in the elderly, gradual changes in body mass, 
serum albumin and body water, and decline in renal 
and hepatic function can alter drug distribution and 
elimination, and therefore increase inter-individual 
variation in the response to the ototoxic agent (17,18). 
Drug metabolism is also influenced by disease 
induced alterations in pharmacokinetic properties, 
producing great variations in the level of the drug or 
chemical within the organism (Tables III, IV). 
Impaired renal and hepatic clearance, hypothyroid-
ism, circulatory insufficiency secondary to cardiac 
failure, and altered drug-binding to plasma proteins 
are all pathological determinants of inter-individual 
variations of drug metabolism. As a consequence, in 
these pathological conditions, dose regimens for 
many drugs must be reduced to avoid drug accumu-
lation and, hence, ototoxic effects (17,18). In older 
patients, changes in the endogenous sensitivity to 
many drugs that may further impair renal blood flow, 
must also be considered. For example, non-steroidal 
anti-inflammatory drugs can decrease the produc-
tion of vasodilating renal prostaglandins, which are 
essential to maintain optimal renal perfusion, thus 
influencing the elimination of a co-administered oto-
toxic drug. Furthermore, in the elderly, the physio-
logical response to an administered drug may change, 
because of a dynamic and time-dependent expres-
sion of specific cellular receptors and ligands, which 
may be temporarily up- or down-regulated by many 
Table I. Principal classes of ototoxic compounds.
Drugs
Aminoglycoside antibiotics streptomycin, gentamycin, neomycin, tobramycin, kanamycin, amicacin, 
netilmycin
Macrolid antibiotics eritromycin, azitromycin, claritromycin
Quinoline anti-malarials choroquine, hydroxychloroquine, quinine
Platinum analog antineoplastics cisplatin, carboplatin, oxaliplatin
loop diuretics furosemide, bumetranide, ethacrynic acid
Acetyl salicylic acid
Chemicals
organic solvents toluene, styrene, xylene, ethylbenzene, chlorobenzene, trichloroethylene, n-exane, 
n-heptane, carbon disulphide
Heavy metals lead, mercury
Asphyxiants carbon monoxide, hydrogen cyanide, acrynitrile
other agents pesticides (organophosphates, paraquat, pyrethroids, hexochlorobenzene)
Table II. Endogenous and exogenous factors that can contribute 
to potentiation of the ototoxic effect.
Genetic 
polymorphisms Exercise
Age Heavy alcohol intake
Gender Heavy smoking
Immunological  
function
Co-exposure to drugs, chemicals, noise
Diet Stress
Table III. Conditions that can induce accumulation of the drug 
following multiple exposure.
Impaired hepatic clearance that reduces the inactivation of the 
drug
Circulatory insufficiency owing to cardiac failure that reduces 
renal and hepatic blood flow
Modified drug binding to plasma proteins
Hypothyroidism
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 Ototoxic agents and hearing loss  3
endogenous and exogenous factors (17,18). Genetic 
variants may also modify the susceptibility of the 
individual subject to the ototoxic effect of the drug. 
Candidate genes for the mediating effect of the oto-
toxic response can be divided into two categories: 
pharmacokinetic and receptor/target. In particular, 
germline variability in genes which encode factors 
that determine the pharmacokinetics of the com-
pound, such as enzymes and transporters, are the 
major determinants of the ototoxic response, since 
they can modify drug levels in the organism. 
However, several genetic polymorphisms in drug 
targets can influence not only the responsiveness 
to the therapeutic effect and the occurrence of 
adverse effects, but also the overall risk of the under-
lying otological disease (19–22). Furthermore, 
several mitochondrial rnA mutations have been 
associated with drug induced hearing loss, especially 
in preterm infants (23–25). Finally, another interest-
ing mechanism that has been shown to influence the 
degree of hearing loss is the synergistic interactions 
between drugs and chemical compounds given previ-
ously or concurrently. Moreover, ototoxicity of spe-
cific agents can also be enhanced as the result of 
a preceding or concurrent noise exposure to a level 
not usually pathological.
A number of drugs have been associated with 
ototoxicity, and some are both ototoxic and nephro-
toxic. The most known ototoxic drugs are: aminogly-
coside antibiotics, macrolide antibiotics, quinoline 
anti-malarials, platinum analog anti-neoplastics, loop 
diuretics and acetylsalicylic acid (26,27).
Aminoglycoside antibiotics
Aminoglycosides (AG) are a group of natural prod-
ucts such as streptomycin, gentamycin, neomycin, 
tobramycin, kanamycin and semisynthetic derivatives 
such as amicacine netilmycin. AG antibiotics are rap-
idly bactericidal, interfering with bacterial protein 
synthesis. After exposure to these agents, high concen-
trations of AG are found in the renal cortex and in 
the inner ear, thus explaining the high propensity for 
nephrotoxicity and ototoxicity of these drugs. As a 
consequence, vestibular and auditory dysfunction can 
follow the treatment of any of the AG. Streptomycin 
and gentamycin are those with the most pronounced 
and harmful effects on vestibular function, whereas 
neomycin, kanamycin and amikacin are the most 
likely cause of hearing loss. AG rapidly enter the cells 
of the cochlea via endocytosis or non-selective cation 
channels and, following continuous treatment, they 
accumulate in the inner ear because of slow plasmatic 
retro-diffusion (28,29). As a consequence, persistent 
elevated plasma concentrations of the drug above 
critical levels correlate with ototoxicity. Cochlear cells 
can retain AG for six months or longer. This finding 
may explain the increased susceptibility of some 
patients to AG induced ototoxicity in the presence of 
a medical history of previous AG treatment. Because 
almost 90% of AG are excreted by glomerular filtra-
tion they can also damage the kidney. In a downward 
spiral, nephrotoxicity can further reduce the excretion 
of the drug, which in turn predisposes to ototoxicity 
(30). Therefore, in the patient treated with AG it is 
advisable to frequently monitor auditory function, the 
plasma levels of the drug, and creatine excretion. 
Additional care has to be taken with children and 
elderly people treated with AG, since they are at 
increased risk of ototoxicity. In these cases, dose reg-
imen, duration of the treatment, concomitant use of 
other drugs or chemical agents, and level of noise 
exposure in occupational or recreational places should 
be taken into consideration. In particular, it has been 
shown that loop diuretics, such as ethacrynic acid and 
furosemide, can potentiate the ototoxic effect of AG; 
exposure to sub-damaging doses of AG can aggravate 
noise induced cochlear damage, and previous expo-
sure to high levels of noise enhances subsequent AG 
ototoxicity (31,32). Preterm infants are especially at 
risk (23–25).
reported incidences of ototoxicity vary widely, 
depending upon subject groups, treatment parame-
ters, assessment methods, and definitional criteria of 
hearing impairment. The estimated incidence of oto-
toxicity, including both cochleotoxicity and vestibu-
lotoxicity, ranges from 15% to 50%, although such 
data include all measurable hearing and balance 
deficits and are not indicative of disabling conditions 
(33,34). AG ototoxic effect results from a progressive 
destruction of vestibular and cochlear sensory cells. 
The degree of dysfunction is directly proportional to 
the dose of the drug and correlates with the number 
of damaged sensory hair cells. The damage progresses 
from the base of the cochlea, where high frequency 
sounds localize, to the apex, where low frequencies 
are detected. once they are damaged, these cells can-
not be replaced so the impairment is permanent.
Several studies indicate that AG antibiotics have 
a wide sphere of action, and might interfere with 
DnA, rnA, protein synthesis, energy metabolism, 
calcium transport, synthesis and degradation of 
Table IV. Mechanisms of interaction between drugs that can 
induce accumulation in the site of action during maintenance 
therapy.
Inhibition of ototoxic drug-metabolizing enzyme induced by 
co-exposed drug
reduction of ototoxic drug-binding to plasma proteins induced 
by co-exposed drug
Inhibition of drug transport into cells induced by co-exposed to 
drug
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prostaglandins, mucopolysaccahrides and lipids (10, 
23,35–37). As a consequence, a wide variety of 
mechanisms has been associated with AG ototoxic-
ity. It has been suggested that AG once entered into 
the outer hair cell can induce cell death by either 
caspase-dependent and caspase-independent mech-
anisms (30,38). In particular, it has been reported 
that AG might form AG-iron complexes within the 
cells, which can react with electron donors to form 
roS. roS, in turn, might activate a number of 
downstream metabolic signalling pathways that can 
trigger apoptosis via caspase activation. In line with 
this, deferoxamine, an iron chelant frequently used 
in clinical practice, partially protects the cochlea 
from the ototoxic effect of AG forming an inactive 
iron-AG complex. on the other hand, the scavenger 
tocopherol reduces AG induced ototoxicity prevent-
ing the production of free radicals. In line with this, 
other antioxidants too, such as aspirin, have been 
shown to protect against aminoglycoside induced 
hearing loss and, importantly, they do so without 
compromising drug serum levels or antibacterial effi-
cacy (39). Genetic factors might also modify the 
sensitivity to AG ototoxicity. In particular, transi-
tional mutations in the mitochondrial small ribo-
somal rnA gene, namely A1555G (and less 
frequently C1494T), have been identified as primary 
genetic traits in aminoglycoside induced deafness 
(40–42). The availability of genetic testing for the 
determination of the A1555G mutation allowed the 
screening of people at potential risk of AG induced 
ototoxicity. recently, it has been suggested that 
genetic deficiency in megalin, an endocytic receptor 
that bonds and internalizes within the cochlea a 
number of substances, including AG, may play a cru-
cial role in AG induced hearing loss (43).
Macrolide antibiotics
Macrolide antibiotics including erythromycin, azith-
romycin and clarithromycin represent the gold stan-
dard therapy in respiratory tract infections and otitis 
media (44–48). The anti-bacterial effect of macrolides 
is due to inhibition of bacterial protein synthesis. The 
ototoxic effect of macrolides appears when they are 
given by intravenous injection at high doses. The 
symptomatology is characterized by an accentuated 
hearing loss, particularly at the beginning of therapy, 
and tinnitus. These symptoms, however, disappear 
after treatment suspension. The mechanism of action 
of macrolide ototoxicity is still unclear.
Quinoline anti-malarials
Quinoline anti-malarials, chloroquine and hydroxy-
chloroquine, initially employed in the prevention and 
treatment of malaria, have been used subsequently 
for the treatment of rheumatoid arthritis and other 
connective tissue diseases (49–52). Besides the well-
known gastrointestinal, neuronal and retinal toxicity, 
prolonged exposure to high cumulative doses of these 
drugs frequently induces irreversible ototoxicity that 
is manifested by sensorineural hearing loss, tinnitus, 
sense of imbalance and cochlea-vestibular symptoms 
(52). These effects are associated with deposition of 
the drug in the internal ear and with several different 
types of injury to the cochlear sensory hair cells, 
decrease in neuronal population, loss of supporting 
hair cells, and atrophy of the stria vascularis (12,53). 
Brainstem auditory evoked potentials appear to be a 
sensitive method for detecting early manifestations 
of cochlear injury caused by these drugs when they 
are still reversible. Anti-malarial quinine, when it is 
given in full therapeutic or excessive doses, can also 
be associated with auditory functional impairment, 
presenting with tinnitus, vertigo and high-frequency 
deafness. Fortunately, although these symptoms 
occur very frequently, they disappear soon after drug 
withdrawal. The auditory effects probably reflect a 
direct neurotoxicity of the eighth nerve, although 
secondary vascular changes may also play a role. on 
the other hand, tinnitus after small doses of quinine 
usually results from drug hypersensitivity (54). 
Platinum analog antineoplastics
Platinum analogs, cisplatin, carboplatin, and oxalip-
latin, are effective and widely used antineoplastic 
agents for the treatment of many types of cancer. 
These drugs enter the malignant cells and inhibit 
DnA replication and transcription; cell death is pri-
marily through apoptosis. Side-effects of platinum 
analogs include ototoxicity, nephrotoxicity, and neu-
rotoxicity. ototoxicity is manifested by otalgia, tin-
nitus, and severe, bilateral, and irreversible 
sensorineural hearing loss (11, 55). High-frequency 
audiometric thresholds are often affected first; pro-
gression to low frequencies may occur with prolonged 
treatment regimens. Elderly and paediatric patients 
are particularly sensitive to platinum analog ototoxic-
ity. High cumulative doses, concomitant noise expo-
sure, co-administration of other ototoxic drugs and/
or chemicals, depleted nutritional condition, renal 
and hepatic insufficiency, anaemia, hypoalbuminae-
mia and prior cranial irradiation usually play a rele-
vant role in the development of ototoxicity for this 
class of drugs (56).
Unfortunately, there is at present no effective 
treatment to prevent ototoxicity, which can be severe 
and disabling. However, adequate hydration and 
increased diuresis are used to prevent renal insuffi-
ciency, which increases the chances for ototoxicity 
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of these drugs (57). In clinical situations, up to 
100% of patients may sustain some degree of hear-
ing loss with prolonged treatment. Various species of 
experimental animals are likewise susceptible to this 
drug and the incidence of hearing loss is generally 
high (57).
Mechanisms of action of platinum analog oto-
toxicity have been only partially understood. Several 
studies suggest that these drugs react with the 
cochlear tissues to generate roS. roS overload 
induces depletion of the cochlear antioxidant defen-
sive enzyme system, preventing scavenging and neu-
tralization of the superoxides generated. Moreover, 
roS may lead to excessive calcium influx in the cell, 
and to an increase of proinflammatory cytokines. 
The uncontrolled increase in roS generation within 
cochlear cells may also activate the pro-apoptotic 
pathways, both caspase-dependent and indepen-
dent, leading to death of the outer hair cells 
(11,55,57). The cell death is time- and drug con-
centration-dependent. Antioxidants have been used to 
decrease platinum analog ototoxicity in animal mod-
els with some success, including glutathione, superox-
ide dismutase, vitamin C, vitamin A, vitamin E, 
and transferases (58). However, clinical studies of 
antioxidant-based amelioration of cisplatin ototox-
icity are minimal (59). Moreover, a potential draw-
back of the administration of antioxidants is the 
potential reduction in anti-tumoural efficacy of the 
drug (60).
There is substantial variability in susceptibility to 
the ototoxic effect of platinum analogs. Many studies 
suggest that several genetic variants can contribute 
to increased sensitivity for platinum analogs’ ototox-
icity (19). In particular, differences in functional 
polymorphisms of glutathione-S-transferases, and in 
two genetic variants in thiopurine-S-methyltrans-
ferase and catechol-o-methyl transferase were found 
to be highly associated with cisplatin induced hearing 
loss (20,61). Moreover, recent studies suggest that 
polymorphisms of megalin gene, a multifunctional 
receptor involved in the transport of several sub-
stances including platinum analogs, may play a cru-
cial role in susceptibility to the ototoxic effect of 
these drugs (21).
Loop diuretics
loop diuretics, furosemide, bumetanide and ethacrynic 
acid, are used in the therapy of oedema, heart failure, 
hypertension and, sometimes, in the management of 
severe hypercalcaemia. The diuretic effect depends on 
the inhibition of the na-K-2Cl cotransporter (nKCC2) 
in the thick ascending loop of Henle (12). on the 
other hand, the mechanism of loop diuretics’ ototoxic-
ity is due to interference with fluid and electrolyte 
balance induced by nKCC2 inhibition, expressed at 
the base of the marginal and dark cells of the stria 
vascularis of the cochlea. Since these cells are respon-
sible for endolymph secretion, it follows that there is 
a consequent drop in the endolymphatic potential 
(26,62,63). ototoxicity for this class of drugs mani-
fests as tinnitus, hearing impairment, deafness, vertigo 
and a sense of fullness in the ears. Hearing impairment 
may appear a few minutes after drug administration 
and regresses in parallel with its elimination. The oto-
toxic effect results usually after elevated parenteral 
doses or rapid intravenous administration, and is espe-
cially evident in patients with renal failure. Ethacrynic 
acid appears to induce ototoxicity more frequently 
than other loop diuretics.
The variations observed in the incidence of oto-
toxicity with different loop diuretics can be partially 
explained by the changing balance between ototoxic 
and diuretic potency. other possible explanations 
include differences in drug metabolism, protein bind-
ing capacity, and different ability of penetration of 
the drug into the cochlea. Synergism of ototoxicity 
may occur when loop diuretics are co-administered 
with AG, platinum analogs, or when noise exposure 
and chemical agents are present in the environment. 
Genetic or acquired defects in several proteins in 
both renal and ear tissues can potentiate the loop 
diuretic ototoxicity (63).
Acetylsalicylic acid
Acetylsalicylic acid (ASA) is one of the most used 
drugs worldwide, with therapeutic effects on fever, 
pain and phlogosis. Besides the well known side- 
effects on the gastrointestinal tract, blood and 
kidney, ASA may induce moderate hearing loss, 
alteration of sound perception and tinnitus. How-
ever, these effects are always reversible after discon-
tinuation of the treatment. Several studies have 
shown a large inter-individual variability in the sus-
ceptibility to ASA ototoxicity (27). The usual targets 
for ASA ototoxic effects are the outer hair cells and 
their motility mechanism, the cochlear blood flow, 
and the spontaneous activity in the cochlear nerve. 
It has been shown that ASA accumulates in the extra-
cellular fluid, modifies ionic equilibrium and reduces 
prostaglandin synthesis in the stria vascularis, thus 
inhibiting the cyclooxygenase, an enzyme that catal-
yses the synthesis of prostaglandins. This inhibition 
leads to vasoconstriction of stria vascularis, and 
inhibits the action potential of the cochlear nerve 
(27,64). The ototoxic effect of ASA occurs when 
high doses of the drug are used, e.g. 6–8 g/day. Side-
effects usually disappear 48 h after the interruption 
of treatment. ASA can potentiate the ototoxic effects 
of several drugs and chemical agents (65).
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Chemical agents
The class of chemical agents investigated as poten-
tial ototoxic compounds includes organic solvents, 
heavy metals, nitriles, asphyxiants, pesticides/herbi-
cides. robust evidence from a large number of ani-
mal studies has demonstrated that many of these 
compounds are potent ototoxic agents (66–69). 
Addition of other stressors, such as exposure to 
impact or continuous noise, and other chemicals or 
ototoxic drugs, can reduce the threshold needed to 
elicit the auditory damage (70–78). However, there 
are no regulations that require monitoring of the 
hearing of workers who are employed at locations in 
which occupational exposure to potentially ototoxic 
chemicals occurs in the absence of noise exposure 
(79). A few human studies, conducted mainly over 
the last three decades, have brought attention to the 
risk of acoustic damage following exposure to chem-
ical agents, and their interaction with noise exposure 
in the workplace. Unfortunately, results of these 
studies were not always consistent and showed lim-
ited generalizability, because of the elevated number 
of existing industrial substances, and because of the 
great individual variability due to several endoge-
nous and exogenous factors. In addition, it is not 
easy to establish a causal relationship between expo-
sure to chemicals and hearing loss, because of insuf-
ficient information about exposure history and a 
lack of comparability between study and control 
groups (80–84). nevertheless, several researches 
suggest that the association between industrial 
chemical exposure and hearing impairment is bio-
logically plausible. Human data support the evi-
dence that structure and toxic properties of the 
chemical agent, past occupational exposure to exces-
sive noise, history of heavy smoking, physical exer-
cise, personal life-style, age of the subject, genetic 
individual variability, pharmacokinetic and pharma-
codynamic subjective variability and pathological 
associated conditions are responsible for the wide 
differences in susceptibility to the hearing damage 
observed (12,18,66,85,86). Evidence from a large 
number of experimental and clinical studies showed 
that most of the chemical agents have many differ-
ent targets for injury within the auditory system, and 
may affect both the cochlea and the central auditory 
pathways, depending on the compound. For chem-
icals such as n-hexane and n-heptane, metals such 
as lead and mercury and organophosphate pesti-
cides, the auditory effects are especially connected 
to an intrinsic neurotoxic action of these substances. 
These compounds exhibit more central neurotoxic 
effects than pure ototoxic effects (87–91), so that 
exposure to these agents may impair not only the 
detection but also the discrimination of sounds. 
Accumulating data link roS production to cochlear 
damage for both chemical agents and noise trauma 
(92). Histological studies on specific chemical agents 
and concomitant noise exposure have demonstrated 
that, during stressful conditions, damage to hair 
cells is caused by a disruption of the intrinsic anti-
oxidant defenses, following overproduction of roS. 
Moreover, reduced blood flow seems to be another 
important ototoxic mechanism shared by both 
chemicals and noise exposure (7,67,92,93). This 
can explain why additional stressors, such as noise 
or drugs, can reduce the chemical exposure thresh-
old needed to elicit a hearing damage, and why a 
single environmental and/or occupational exposure 
to a specific chemical agent may not elicit an oto-
toxic response, whereas the same exposure in the 
presence of a high level of noise can lead to oxidative 
stress and to the death of cells in the inner ear 
(77,78,94–96).
Noise exposure
Exposure to high intensity and/or prolonged noise 
and vibrations causes temporary or permanent 
threshold shifts in auditory perception reflected by 
reversible or irreversible, often bilateral, sensorineu-
ral damage that starts within the outer hair cells and 
progressively spreads over the entire cochlea. As 
mentioned before, many studies have shown that 
hearing loss produced by excessive noise exposure 
can be added to the effects induced by co-exposure 
to chemical agents. However, intense noise or vibra-
tions are often present in many occupational work-
places (e.g. industrial, manufacturing, construction, 
and military) where exposure to chemicals can also 
occur. Therefore, in the majority of cases, the hearing 
loss observed in these settings is not solely imputable 
to a single agent.
The damaging properties of noise exposure 
depend in part on the characteristics of the sound 
reaching the sensory structures in the inner ear. The 
characteristics of noise regarded as critical (harm-
ful) are: intensity, sound spectrum, duration and 
temporal distribution during the day, week, or 
month. However, wide variations in the subjective 
response may be present, due to genetic susceptibil-
ity, young and elderly age, pathological comorbidi-
ties, preceding exposure to ototoxic drugs or 
chemical agents, vibrations, and personal life-style. 
Gender and race seem to be also associated with 
susceptibility to noise induced hearing loss (96–
100). Exposure to damaging levels of sound occurs 
in two forms. High intensity sounds can physically 
damage hair cells stereocilia, disrupt the permeabil-
ity of the strial blood-labyrinth barrier, and induce 
a reduction or loss of the electrical endocochlear 
potential. Moreover, high intensity sounds can 
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induce physical disruption of the organ of Corti, 
increased cellular endocytosis, elevated calcium 
intracellular concentrations, and mitochondrial 
lesions with release of mitochondrial pro-apoptotic 
factors into the cytosol (6,17,66). long-term expo-
sure to lower intensity noise generates high levels of 
metabolic activity and formation of roS coupled 
with physiological changes in the blood-labyrinth 
barrier, resulting in temporary auditory dysfunction 
and often permanent hearing loss. High levels of 
metabolic activity and formation of free radicals 
may continue for several days after cessation of the 
sound exposure (6,9,14–16,101,102). In the pres-
ence of drugs or chemical compounds that interfere 
with intracellular calcium regulation in the outer 
hair cells, these can be more vulnerable to excessive 
levels of noise. This interaction is imputable to outer 
hair cells being electromotile, i.e. the cells change 
their length in response to sound stimulation, and 
this process is controlled by the calcium concentra-
tion within the cell.
Concluding remarks
The examples presented in this review illustrate the 
potential for many commonly used drugs and chem-
ical agents, as well as noise exposure, to contribute 
significantly to ototoxicity in man. However, although 
aminoglycoside and macrolide antibiotics, quinoline 
antimalarials, platinum analog antineoplastics, loop 
diuretics, and acetylsalicylic acid are well character-
ized molecules and their clinical adverse effects are 
well established, the exact mechanisms by which 
they may induce their toxic effects and auditory 
impairment are not fully established. The contribu-
tion of oxidative stress is emerging as one of the 
most important mechanism in the pathophysiology 
of hearing loss, but it is clear that more data are 
required to provide insight into individual suscepti-
bility to specific roS-dependent mechanisms of 
toxicity. Understanding individual differences of this 
type and the potential for redox effects to manifest 
as toxicities is increasingly valuable, not just for 
existing therapies, but for tailoring clinical drug 
development. More research is also needed to 
address the complex interplay between endogenous 
and exogenous factors underlying ototoxicity and 
the tangled net of interactions among drugs, chem-
icals and noise exposure. Investigation of the oto-
toxic properties of different compounds and the 
underlying pathophysiologic variables is important, 
not only for medical progress and researches pur-
poses, but also to establish recommendations for 
good health in the workplace, and to identify best 
practices for hearing loss prevention. 
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